Clinical trials: Malaria
Malaria
A Study to Assess the Safety and Immunogenicity of the Malaria Vaccine, R21, Administered With and Without Matrix-M1
This is a clinical trial in which healthy volunteers will be administered one or two experimental malaria vaccines. The vaccine R21 will either be administered alone or in combination with the adjuvant vaccine Matrix-M1.
- Trial name
- NCT02572388
- Testing
- R21, Matrix-M1
- Where
- 2 sites in United Kingdom
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Malaria
A FIH Study to Investigate the Safety, Tolerability and PK of P218
The First in Human (FIH) study is separated into two parts: The first part is a Single Ascending Dose (SAD), double-blinded, randomized and placebo-controlled, including 8 cohorts of 8 subjects (2 placebo and 6 on active drug).
- Trial name
- NCT02885506
- Testing
- Oral administration of P218 capsules
- Where
- United Kingdom
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Plasmodium Falciparum Malaria
Phase I/II Trial of a Malaria Vaccine in Adults Living in the United States of America
Phase I/II Trial of a Malaria Vaccine, FMP011/AS01B, in Adults Living in the United States of America.
- Trial name
- NCT00312663
- Testing
- Falciparum Malaria Protein 11 with AS01B adjuvant.
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Sickle Cell Anemia, Sickle Cell Disease
Novel Use Of Hydroxyurea in an African Region With Malaria
Multiple studies have shown that hydroxyurea has clinical efficacy in preventing acute painful episodes and reducing the need for blood transfusions in children with sickle cell anemia (SCA), but no study has been conducted in…
- Conditions
- Sickle Cell Anemia, Sickle Cell Disease, Malaria
- Trial name
- NOHARM (NCT01976416)
- Testing
- Hydroxyurea
- Where
- Uganda
- Volunteers
- 208 people
- Sponsor
- Indiana University
Malaria
Safety, Immunogenicity, and Protective Efficacy of Two Regimens of Radiation Attenuated Plasmodium Falciparum NF54 Sporozoites (PfSPZ Vaccine) During Natural Transmission Season in Healthy African Adults in Mali
Background: The disease malaria affects many people in Mali and other parts of Africa and the world. It is caused by germs spread by mosquito bites. Malaria may be mild.
- Trial name
- NCT03510481
- Testing
- PfSPZ Vaccine, Normal Saline, artemether 20mg/lumefantrine 120mg (AL)
- Where
- Mali
- Volunteers
- 478 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Falciparum
Study to Compare the Triple ACT AL+AQ With the ACT AL in Cambodia and Vietnam
This study is a multi-centre, open-label randomised trial to assess the efficacy, safety and tolerability of the Triple ACT artemether-lumefantrine+amodiaquine (AL+AQ) compared to the ACT artemether-lumefantrine (AL) in…
- Trial name
- TACT-CV (NCT03355664)
- Testing
- ACT, TACT
- Where
- 4 sites in Cambodia, Vietnam
- Volunteers
- 310 people
- Sponsor
- University of Oxford
Malaria, Vivax, G6PD Deficiency
Assessing a Risk Model for G6PD Deficiency
A clinical study designed to develop and inform an individual risk of hemolysis model based on individual red blood cell G6PD levels.
- Trial name
- NCT03337152
- Testing
- primaquine, chloroquine + primaquine
- Where
- Thailand
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- PATH
Malaria, Plasmodium Vivax
Study of VMP001 and AS01B (Adjuvant Formulation) in Healthy Malaria-Naïve Adults
This is a first-in-humans safety, immunogenicity and efficacy study with recombinant protein VMP001, a Plasmodium vivax circumsporozoite (CS) protein based vaccine.
- Trial name
- NCT01157897
- Testing
- VMP001, P. vivax sporozoite challenge
- Where
- United States
- Volunteers
- 41 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria
Gut and Azithromycin Mechanisms in Infants and Children II
Childhood mortality is decreasing worldwide. However, many sub-Saharan countries still have high children under 5 mortality rates.
- Trial name
- GAMINII (NCT04315272)
- Testing
- Azithromycin
- Where
- Burkina Faso
- Volunteers
- 449 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Malaria
Safety and Immunogenicity of GSK Biologicals' Investigational Malaria Vaccine in HIV Infected Infants and Children
The purpose of this study is to assess the safety and immunogenicity of the candidate malaria vaccine in HIV-infected infants and children
- Trial name
- NCT01148459
- Testing
- GSK Biological's Investigational Malaria Vaccine 257049, Human Diploid Cell Vaccine (HDCV) or Purified Vero Cell Rabies Vaccine (PVRV, Verorab) (Aventis Pasteur);, Purified Chick Embryo Cell Culture (PCEC) Rabies Vaccine (Rabipur or equivalent) (Novartis).
- Where
- 2 sites in Kenya
- Volunteers
- 200 people
- Sponsor
- GlaxoSmithKline
Covid19, Paludism
Malaria as a Protection Factor Against Severe COVID-19 (Known as SARS-COV-2) in the Democratic Republic of Congo (Palu-COVID)
In this study, the investigators will explore the reasons for the apparently lower proportion of severe COVID-19 cases in many sub-Sahara African countries.
- Trial name
- Palu-COVID (NCT05012280)
- Where
- Democratic Republic of the Congo
- Volunteers
- 238 people
- Sponsor
- Institute of Tropical Medicine, Belgium
Malaria
A Study to Assess Safety of Current Standard Malaria Treatment and an Assessment of G6PD Status in South-east Bangladesh
This is a study assessing safety and efficacy of current national guidelines for the treatment of uncomplicated malaria in Bangladesh as well as to assess the G6PD status among the enrolled patients.
- Trial name
- NCT02389374
- Testing
- chloroquine, Artemether-lumefantrine combination, Primaquine
- Volunteers
- 181 people
- Sponsor
- Menzies School of Health Research
Malaria
Sanaria PfSPZ Challenge With Pyrimethamine or Chloroquine Chemoprophylaxis Vaccination (PfSPZ-CVac Approach): A Randomized Double Blind Placebo Controlled Phase I/II Trial to Determine Safety and Protective Efficacy Against Natural Plasmodium Falcipa...
Background: Malaria remains a major global health problem. Malaria is spread by the bite of mosquitos. Africa is the region of the world where most people get malaria. Sanaria PfSPZ Challenge is a malaria vaccine.
- Trial name
- NCT03952650
- Testing
- Chloroquine Phosphate, PfSPZ Challenge, Pyrimethamine
- Where
- Mali
- Volunteers
- 252 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, HIV Infections
HIV Protease Inhibitors for the Prevention of Malaria in Ugandan Children
HIV and malaria are major causes of morbidity and mortality in Sub-Saharan Africa and children bear the greatest brunt of both diseases. No single existing intervention is likely to control malaria in Africa.
- Trial name
- PROMOTE-PEDS (NCT00978068)
- Testing
- Lopinavir/Ritonavir (LPV/r), Nevirapine (NVP), Efavirenz (EFV)
- Where
- Uganda
- Volunteers
- 176 people, healthy volunteers welcome
- Sponsor
- University of California, San Francisco
Plasmodium Falciparum Malaria
Phase 1 Trial of a Malaria Vaccine in Young Kenyan Children
To assess the safety and reactogenicity of the FMP-1/AS02A malaria vaccine in malaria-exposed children living in western Kenya and aged 12-47 months
- Trial name
- NCT00317473
- Testing
- FMP1/AS02A Malaria vaccine, Imovax Rabies vaccine
- Where
- Kenya
- Volunteers
- 135 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Malaria Falciparum, Malaria Vivax
A Study to Investigate the Safety, Tolerability and Pharmacokinetics of OZ439 in Healthy Male and Female Subjects
OZ439 is a synthetic trioxolane that has potential value as a peroxide antimalarial agent. This was a Phase I, single-centre, multi-component, double-blind, randomised, placebo-controlled study in healthy male and female…
- Conditions
- Malaria Falciparum, Malaria Vivax, Healthy Volunteers
- Trial name
- NCT00928083
- Testing
- OZ439 50mg API capsules, OZ439 200mg API capsules, OZ439 400mg aqueous dispersion
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Infections, Vector Borne Diseases
Phase 1b MMV367 PK/PD and Safety in Healthy Adult Volunteers Experimentally Infected With Blood Stage P. Falciparum
This is an open-label, adaptive study using the P. falciparum induced blood stage malaria (IBSM) model to characterise the pharmacokinetic/pharmacodynamic (PK/PD) profile and safety of MMV367 (the IMP).
- Conditions
- Infections, Vector Borne Diseases, Systemic Inflammatory Response Syndrome, Inflammation
- Trial name
- NCT05979207
- Testing
- MMV367 3mg, P. falciparum IBSM infection, MMV367 5mg
- Where
- 2 sites in Australia
- Volunteers
- 12 people, healthy volunteers welcome
- Sponsor
- Medicines for Malaria Venture
Malaria
Pyronaridine Artesunate (3:1) in Children and Adults With Acute Plasmodium Vivax Malaria
The purpose of this study is to compare the efficacy and safety of the fixed combination of pyronaridine artesunate (Pyramax®, PA) (180:60 mg) with that of standard chloroquine therapy in children and adults with acute…
- Trial name
- NCT00440999
- Testing
- Pyronaridine artesunate, Chloroquine
- Where
- 5 sites in Cambodia, India and 2 more
- Volunteers
- 456 people
- Sponsor
- Medicines for Malaria Venture
Malaria
L9LS MAb in Malian Infants
The purpose of this study is to assess the safety, tolerability, and pharmacokinetics of L9LS in infants in Mali and to evaluate the impact of L9LS on subsequent R21/Matrix-MTM vaccine immunogenicity.
- Trial name
- NCT06461026
- Testing
- L9LS, R21/Matrix-MTM
- Where
- 3 sites in Mali
- Volunteers
- 327 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Malaria, Plasmodium Falciparum Malaria
FMP2.1/AS02A: Rabies Vaccine Malaria-Experienced Adults in Bandiagara, Mali
Malaria is a disease that affects many people in Africa and in Mali. It is caused by germs that are spread by mosquito bites. This study will look at the safety, effectiveness, and best dose of an experimental malaria vaccine in…
- Trial name
- NCT00349713
- Testing
- FMP2.1/AS02A, Rabies vaccine (RabAvert)
- Where
- Mali
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command